Showing results (21-30 of 141) with videos related to

Sort By:
Pageof 15
Haematologica|October 18, 2006
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II studyJean-Luc Harousseau, Michel Attal, Xavier Leleu, et al.
International Journal of Radiation Oncology, Biology, Physics|September 29, 2022
Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple MyelomaAxel Cailleteau, Philippe Maingon, Sylvain Choquet, et al.
Future Oncology (London, England)|January 10, 2024
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practiceXavier Leleu, Hans C Lee, Jeffrey A Zonder, et al.
The New England Journal of Medicine|December 26, 2003
Single versus double autologous stem-cell transplantation for multiple myelomaMichel Attal, Jean-Luc Harousseau, Thierry Facon, et al.
Clinical Hematology International|February 13, 2023
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)Zoe van de Wyngaert, Florent Malard, Cyrille Hulin, et al.
Cancer|August 8, 2013
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myelomaGuillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM StudyClément Bailly, Thomas Carlier, Bastien Jamet, et al.
Blood|February 23, 2024
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myelomaCyrille Touzeau, Aurore Perrot, Cyrille Hulin, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
JMIR Formative Research|February 25, 2026
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)Alexis Talbot, Bernard Delcour, Laurent Gillot, et al.
Pageof 15